Specialty Pharmacy

GREENVILLE, N.C. — Mayne Pharma on Thursday announced that it had acquired a portfolio of dermatology foam products from GSK in $50.1 million deal. Among the portfolio’s products are U.S. rights to acne treatment Fabior (tazarotene) foam and plaque psoriasis treatment Sorilux (calcipotriene) foam. The company also gains the Canadian rights to Luxiq and Olux-E, as well as Mexican rights to betamethasone foam. 

 

CHESTERFIELD, U.K. — Mallinckrodt announced Thursday that it would be building a new campus for its specialty brands organization in Bedminster, N.J.’s Somerset Financial Center. The company will invest more than $80 million in New Jersey, and expects that some 400 employees will occupy the new space in the first quarter of 2017. The new location will consolidate the operations for its specialty brands groups.

 

FLINT, Mich. — Diplomat Pharmacy announced Monday that it is now filling prescriptions for the recently approved Zinbryta (daclizumab), a drug to treat relapsing forms of multiple sclerosis. The drug is generally reserved for patients with inadequate responses to two or more MS therapies. 

 

“A relapse of any kind can cause a person to lose hope,” Diplomat president Gary Kadlec said. “For people with relapsing multiple sclerosis, Zinbryta has the potential to restore that hope and make life a little easier.”

LENEXA, Kan. — Healthcare software company Mediware Information Systems announced Wednesday that its CareTrend platform is now available for specialty pharmacies. The new platform looks to simplify prescription procession, pharmacy workflow, reimbursement and reporting. 

 

FLINT, Mich. — Diplomat Pharmacy on Tuesday announced the results of its second quarter, reporting total revenue of $1.09 billion, a 35% increase over the same quarter in 2015.